Newpath Partners logo

Newpath Partners

Crunchbase
Pitchbook

Deals on record

4

Common Fundraising Type

Equity

nChroma Bio logo
nChroma Bio

Epigenetic editing

Wilson Sonsini Goodrich & Rosati logo
Wellington Management logo
T. Rowe Price logo
Sofinnova Partners logo
Sixth Street logo
Omega Funds logo
Mubadala Capital logo
Menlo Ventures logo

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Equity
$75M
12/11/2024
Article
Metsera logo
Metsera

Biopharmaceutical

Venrock logo
Wellington Management logo
T. Rowe Price logo
SymBiosis logo
SoftBank logo
Newpath Partners logo
Janus Henderson logo
GV logo

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Series B
$215M
11/13/2024
Article
Leal Therapeutics logo
Leal Therapeutics

Biotechnology

Chugai Venture Fund logo
Newpath Partners logo
PhiFund logo
OrbiMed logo
Euclidean Capital logo
Alexandria Venture Investments logo

Leal Therapeutics is a biotechnology company developing treatments for central nervous system disorders, focusing on amyotrophic lateral sclerosis (ALS) and schizophrenia.

Equity
$45M
10/30/2024
Article
Magnet Biomedicine logo
Magnet Biomedicine

Biotechnology

Newpath Partners logo
ARCH Venture Partners logo

Magnet Biomedicine is a biotechnology company that develops TrueGlues compounds to induce cooperative protein-protein interactions, aiming to optimize therapeutic impact and address undruggable proteins in areas such as cancer, cardiovascular disease, and immune disorders.

Equity
$50M
09/19/2023
Article